Trial Profile
Treatment-free Remission Accomplished With Dasatinib in Patients With CML
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms TRAD
- 01 Dec 2023 Results (n=55) assessing whether dasatinib therapy after TFR1 failure post-imatinib discontinuation could improve the likelihood of TFR2 published in the British Journal of Haematology
- 13 Dec 2022 Results of a risk factor analysis associated with TRF2 failure for treatment-free remission failure with a median follow-up duration of 27.5 months presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 17 Jun 2022 Results assessing treatment-free remission 2 rate after dasatinib discontinuation in patients with chronic myeloid leukaemia, presented at the 27th Congress of the European Haematology Association.